Essex Investment Management Co. LLC trimmed its position in Misonix, Inc. (NASDAQ:MSON) by 10.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 92,269 shares of the medical equipment provider’s stock after selling 10,464 shares during the period. Essex Investment Management Co. LLC owned 0.96% of Misonix worth $1,855,000 at the end of the most recent reporting period.
A number of other large investors have also recently made changes to their positions in MSON. Strs Ohio bought a new position in Misonix in the 2nd quarter valued at $50,000. Wells Fargo & Company MN raised its position in shares of Misonix by 6.2% during the 2nd quarter. Wells Fargo & Company MN now owns 12,369 shares of the medical equipment provider’s stock valued at $313,000 after buying an additional 724 shares in the last quarter. JPMorgan Chase & Co. purchased a new stake in shares of Misonix during the 2nd quarter valued at $49,000. WealthTrust Axiom LLC purchased a new stake in shares of Misonix during the 2nd quarter valued at $208,000. Finally, Acadian Asset Management LLC raised its position in shares of Misonix by 3.1% during the 2nd quarter. Acadian Asset Management LLC now owns 19,132 shares of the medical equipment provider’s stock valued at $486,000 after buying an additional 574 shares in the last quarter. 27.36% of the stock is owned by hedge funds and other institutional investors.
MSON has been the topic of several research reports. BTIG Research restated a “buy” rating and set a $27.00 price objective on shares of Misonix in a research report on Thursday, August 15th. Canaccord Genuity restated a “buy” rating and set a $30.00 price objective (up previously from $24.00) on shares of Misonix in a research report on Thursday, August 15th. ValuEngine cut shares of Misonix from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, BidaskClub upgraded shares of Misonix from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, July 3rd. One research analyst has rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $28.50.
Misonix (NASDAQ:MSON) last issued its earnings results on Wednesday, August 14th. The medical equipment provider reported ($0.11) EPS for the quarter. The business had revenue of $9.75 million during the quarter. Misonix had a negative return on equity of 25.99% and a negative net margin of 19.01%.
Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacific, Africa, and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.
See Also: High-Yield Dividend Stocks
Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.